+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID06560112

Phase II Study Evaluating Combination Therapy with AK104, AK112, and Chemotherapy in Women with Recurrent Ovarian Cancer

Led by Akeso · Updated on 2025-03-12

172

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a combination therapy using two investigational drugs, AK104 and AK112, along with chemotherapy in women with recurrent ovarian cancer. This Phase 2, open-label, multi-center study focuses on high-grade epithelial ovarian cancer that has returned after prior platinum-based chemotherapy treatments. AK104 targets CTLA-4 and PD-1 proteins, while AK112 targets VEGF and PD-1, both aiming to affect tumor growth and immune response. The study includes multiple groups receiving different combinations of AK104, AK112, and chemotherapy. Some groups receive AK104 every six weeks combined with AK112 every three weeks, while others receive these drugs with chemotherapy administered every three weeks. The treatment schedules are designed to assess how these combinations work together in various dosing regimens. Participants will have their cancer response measured using standard imaging criteria over up to two years. They will be closely monitored for side effects and survival outcomes during this period. The research team will collect tumor tissue samples and assess organ function, as well as track adverse events. The study aims to provide detailed information on the response rate, progression-free survival, duration and time to response, and overall survival in women participating in the trial.

CONDITIONS

Brief Title

An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Research Team

T

Ting Liu, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here